Skip to main content
OpenTrials
Completed

NCT Number: NCT02691520

Epidemiology of Treatment Resistant Depression in Taiwan

The purpose of this study is to assess the epidemiology of Treatment Resistant Depression (TRD) in the nationally insured population in Taiwan including incidence, duration of clinical episodes, and prevalence by age and sex.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

This is a retrospective study of approximately one million subjects randomly selected from an anonymized database National Health Insurance Research Database (NHIRD). Participants aged 18 years or older who have had neither a depression diagnosis nor a dispensing of an antidepressant medication in the last four months of 2004 will enter the study when they receive in 2005 a depression diagnosis and a dispensing of an antidepressant medication within 30 days of each other and will be followed up to 8 years or until they have 4 months with neither a depression diagnosis nor a dispensing of an antidepressant medication. Treatment Resistant Depression (TRD) Incidence, TRD prevalence by age and sex and duration of clinical episodes will be estimated.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants who have been continuously enrolled in the insurance plan since January 1, 2004 (ignoring breaks of less than 30 days) and have not received an exclusion diagnosis and during the last 4 months of 2004, a) Have not received a diagnosis of depression and b) Have not received a dispensing of an AD medication
  • Participants with a diagnosis of a depressive disorder including dysthymic disorder (International Classification of Diseases [ICD]-9 codes 296 depression-related, 300.4, 311) and Major Depressive Disorder (ICD-9 296.2, 296.3) will be followed through December 31, 2013

Exclusion criteria

  • Participants who receive following diagnosis will be excluded, a) Mania, b) Schizophrenia (ICD-9 codes 295), c) Bipolar disorder (ICD-9 codes 296 bipolar-related), D) Dementia (ICD-9 codes 290 or 294); Note: Major depressive disorder (MDD) with psychotic behavior (ICD 296.24 for single episode, ICD 296.34 for recurrent episode) is not an exclusion

Treatment and study plan

Primary outcomes

  1. Incidence Percentage of Participants with Treatment Resistant Depression

    Time frame: Approximately 8 Years

    The percentage of beneficiaries of Taiwan's health insurance plan who developed treatment resistant depression during 2005

  2. Prevalence Percentage of Participants with Treatment Resistant Depression

    Time frame: Approximately 8 Years

  3. Duration of an episode of Depression

    Time frame: Approximately 8 Years

    Time from onset of depression to cessation of depression visits and medications.

Secondary outcomes

  1. Healthcare costs

    Time frame: Approximately 8 Years

    Direct healthcare cost associated with depression treatment will be assessed.

  2. Number of Participants With Comorbidities

    Time frame: Approximately 8 Years

  3. Medications used by Participants with Treatment Resistant Depression

    Time frame: Approximately 8 Years

Sponsors and collaborators

Lead sponsor

Janssen Research & Development, LLC

Industry

Collaborators

  • Elysia Group

Registry information

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Feb 25, 2016
Registry last updated
Oct 28, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.